New insights into antigen specific immunotherapy for chronic myeloid leukemia

Cancer Cell International

Volumn 12, Issue , 2012, Pages

  Li, Yangqiu ^a,b   Lin, Chen ^a   Schmidt, Christian A ^c  

^a MEDICAL COLLEGE OF JINAN UNIVERSITY   (China)

^b JINAN UNIVERSITY   (China)

^c UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

BCR ABL; Chronic myeloid leukemia; Immunotherapy; Vaccine

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; DENDRITIC CELL VACCINE; IMATINIB; LEUKEMIA ANTIGEN; ONCOPROTEIN; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CHRONIC MYELOID LEUKEMIA; DONOR LYMPHOCYTE INFUSION; DRUG TARGETING; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNE RESPONSE; LEUKEMIA CELL; NEPHROBLASTOMA; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE RECEPTOR GENE; TUMOR GENE;

EID: 84870918812     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-12-52     Document Type: Review

References (72)

1. Cortes J, Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012, 120(7):1390-1397. 10.1182/blood-2012-03-378919, 22613793.
2. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010, 3:47. 10.1186/1756-8722-3-47, 3000369, 21108851.
3. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol 2011, 4:6. 10.1186/1756-8722-4-6, 3041785, 21299849.
4. Rohon P. Biological therapy and the immune system in patients with chronic myeloid leukemia. Int J Hematol 2012, 96(1):1-9. 10.1007/s12185-012-1116-8, 22661045.
5. Sokal JE, Aungst CW, Snyderman M, Gomez G. Immunotherapy of chronic myelocytic leukemia: effects of different vaccination schedules. Ann N Y Acad Sci 1976, 277(00):367-383.
6. Chen S, Yang L, Chen S, Li Y. TCR zeta chain expression in T cells from patients with CML. Hematology 2009, 14(2):95-100. 10.1179/102453309X385241, 19298721.
7. Chen X, Woiciechowsky A, Raffegerst S, Schendel D, Kolb HJ, Roskrow M. Impaired expression of the CD3-zeta chain in peripheral blood T cells of patients with chronic myeloid leukaemia results in an increased susceptibility to apoptosis. Br J Haematol 2000, 111(3):817-825. 10.1046/j.1365-2141.2000.02415.x, 11122143.
8. Li Y. Alterations in the expression pattern of TCR zeta chain in T cells from patients with hematological diseases. Hematology 2008, 13(5):267-275. 10.1179/102453308X343482, 18854088.
9. Li Y, Geng S, Du X, Chen S, Yang L, Wu X, Li B, Schmidt CA, Przybylski GK. Restricted TRBV repertoire in CD4+ and CD8+ T-cell subsets from patients with CML. Hematology 2011, 16(1):43-49. 10.1179/102453311X12902908411634, 21269567.
10. Li Y, Geng S, Yin Q, Chen S, Yang L, Wu X, Li B, Du X, Schmidt CA, Przybylski GK. Decreased level of recent thymic emigrants in CD4+ and CD8 + T cells from patients with CML. J Transl Med 2010, 8:47. 10.1186/1479-5876-8-47, 2880023, 20470401.
11. Rezvany MR, Jeddi-Tehrani M, Osterborg A, Kimby E, Wigzell H, Mellstedt H. Oligoclonal TCRBV gene usage in B-cell chronic lymphocytic leukemia: major perturbations are preferentially seen within the CD4 T-cell subset. Blood 1999, 94(3):1063-1069.
12. Torelli GF, Paolini R, Tatarelli C, Soriani A, Vitale A, Guarini A, Santoni A, Foa R. Defective expression of the T-cell receptor-CD3 zeta chain in T-cell acute lymphoblastic leukaemia. Br J Haematol 2003, 120(2):201-208. 10.1046/j.1365-2141.2003.04044.x, 12542476.
13. Wang L, Zhu K, Zha X, Chen S, Yang L, Chen S, Li Y. Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia. J Hematol Oncol 2010, 3:14. 10.1186/1756-8722-3-14, 2859394, 20377918.
14. Zha X, Chen S, Yang L, Shi L, Li B, Wu X, Lu Y, Li Y. Up-regulated TCRζ enhances interleukin-2 production in T-cells from patients with CML. DNA Cell Biol 2012, 31(11):1628-1635. 10.1089/dna.2012.1798, 23057733.
15. Chen J, Schmitt A, Chen B, Rojewski M, Ringhoffer M, von Harsdorf S, Greiner J, Guillaume P, Döhner H, Bunjes D, Schmitt M. Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro. Cancer Immunol Immunother 2007, 56(6):849-861. 10.1007/s00262-006-0232-9, 17009043.
16. Zha X, Chen S, Yang L, Li B, Chen Y, Yan X, Li Y. Characterization of the CDR3 structure of Vβ21 T cell clone in patients with P210BCR-ABL-positive CML and B-ALL. Hum Immunol 2011, 72(10):798-804. 10.1016/j.humimm.2011.06.015, 21820025.
17. Müller L, Pawelec G. Chronic phase patients with CML possess T cells capable of recognising autologous tumour cells. Leuk Lymphoma 2002, 43(5):943-951.
18. Mumprecht S, Schürch C, Schwaller J, Solenthaler M, Ochsenbein AF. Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 2009, 114(8):1528-1536. 10.1182/blood-2008-09-179697, 19420358.
19. Matte-Martone C, Venkatesan S, Tan HS, Athanasiadis I, Chang J, Pavisic J, Shlomchik WD. Graft-versus-leukemia (GVL) against mouse blast-crisis chronic myelogenous leukemia (BC-CML) and chronic-phase chronic myelogenous leukemia (CP-CML): shared mechanisms of T cell killing, but programmed death ligands render CP-CML and not BC-CML GVL resistant. J Immunol 2011, 187(4):1653-1663. 10.4049/jimmunol.1100311, 3150287, 21768400.
20. Ribas A. Tumor Immunotherapy Directed at PD-1. N Engl J Med 2012, 366(26):2517-2519. 10.1056/NEJMe1205943, 22658126.
21. Vonka V. Immunotherapy of chronic myeloid leukemia: present state and future prospects. Immunotherapy 2010, 2(2):227-224. 10.2217/imt.10.2, 20635930.
22. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A. Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 1995, 85(10):2680-2684.
23. Bocchia M, Korontsvit T, Xu Q, Mackinnon S, Yang SY, Sette A, Scheinberg DA. Specific human cellular immunity to bcr-abl oncogene-derived peptides. Blood 1996, 87(9):3587-3592.
24. Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J, Lai L, Jimenez J, Kolitz J, Scheinberg DA. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000, 95(5):1781-1787.
25. Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB, Scheinberg DA. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004, 103(3):1037-1042.
26. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA. Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 2005, 90(10):1324-1332.
27. Bocchia M, Defina M, Aprile L, Ippoliti M, Crupi R, Rondoni M, Gozzetti A, Lauria F. Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination. Nat Rev Clin Oncol 2010, 7(10):600-603. 10.1038/nrclinonc.2010.141, 20808301.
28. Rojas JM, Knight K, Wang L, Clark RE. Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007, 21(11):2287-2295. 10.1038/sj.leu.2404858, 17637811.
29. Jain N, Reuben JM, Kantarjian H, Li C, Gao H, Lee BN, Cohen EN, Ebarb T, Scheinberg DA, Cortes J. Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial. Cancer 2009, 115(17):3924-3934. 10.1002/cncr.24468, 19536894.
30. Bui MR, Hodson V, King T, Leopold D, Dai S, Fiolkoski V, Oakes S, Duke R, Apelian D, Franzusoff A, DeGregori J. Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model. Vaccine 2010, 28(37):6028-6035. 10.1016/j.vaccine.2010.06.085, 3066561, 20619375.
31. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003, 17(7):1301-1312. 10.1038/sj.leu.2402988, 12835718.
32. Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H. Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 2002, 99(9):3272-3279. 10.1182/blood.V99.9.3272, 11964293.
33. Oji Y, Oka Y, Nishida S, Tsuboi A, Kawakami M, Shirakata T, Takahashi K, Murao A, Nakajima H, Narita M, Takahashi M, Morita S, Sakamoto J, Tanaka T, Kawase I, Hosen N, Sugiyama H. WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient. Eur J Haematol 2010, 85(4):358-360. 10.1111/j.1600-0609.2010.01497.x, 20633041.
34. Greiner J, Ringhoffer M, Taniguchi M, Schmitt A, Kirchner D, Krähn G, Heilmann V, Gschwend J, Bergmann L, Döhner H, Schmitt M. Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 2002, 30(9):1029-1035. 10.1016/S0301-472X(02)00874-3, 12225794.
35. Greiner J, Schmitt M. Leukemia-associated antigens as target structures for a specific immunotherapy in chronic myeloid leukemia. Eur J Haematol 2008, 80(6):461-468. 10.1111/j.1600-0609.2008.01053.x, 18284627.
36. Gannagé M, Abel M, Michallet AS, Delluc S, Lambert M, Giraudier S, Kratzer R, Niedermann G, Saveanu L, Guilhot F, Camoin L, Varet B, Buzyn A, Caillat-Zucman S. Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J Immunol 2005, 174(12):8210-8218.
37. Greiner J, Ringhoffer M, Taniguchi M, Hauser T, Schmitt A, Döhner H, Schmitt M. Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int J Cancer 2003, 106(2):224-231. 10.1002/ijc.11200, 12800198.
38. Tschiedel S, Gentilini C, Lange T, Wölfel C, Wölfel T, Lennerz V, Stevanovic S, Rammensee HG, Huber C, Cross M, Niederwieser D. Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia. Leukemia 2008, 22(8):1542-1550. 10.1038/leu.2008.107, 18496563.
39. Smahel M. Antigens in chronic myeloid leukemia: implications for vaccine development. Cancer Immunol Immunother 2011, 60(12):1655-1668. 10.1007/s00262-011-1126-z, 22033582.
40. Zheng H, Chen Y, Chen S, Niu Y, Yang L, Li B, Lu Y, Geng S, Du X, Li Y. Expression and distribution of PPP2R5C gene in leukemia. J Hematol Oncol 2011, 4:21. 10.1186/1756-8722-4-21, 3117819, 21548944.
41. Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM, Goldman JM, Barrett AJ. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 2008, 22(9):1721-172. 10.1038/leu.2008.161, 2574650, 18548092.
42. Al Qudaihi G, Lehe C, Dickinson A, Eltayeb K, Rasheed W, Chaudhri N, Aljurf M, Dermime S. Identification of a novel peptide derived from the M-phase phosphoprotein 11 (MPP11) leukemic antigen recognized by human CD8+ cytotoxic T lymphocytes. Hematol Oncol Stem Cell Ther 2010, 3(1):24-33.
43. Ochi T, Fujiwara H, Suemori K, Azuma T, Yakushijin Y, Hato T, Kuzushima K, Yasukawa M. Aurora-A kinase: a novel target of cellular immunotherapy for leukemia. Blood 2009, 113(1):66-74. 10.1182/blood-2008-06-164889, 18820130.
44. Lindner I, Kharfan-Dabaja MA, Ayala E, Kolonias D, Carlson LM, Beazer-Barclay Y, Scherf U, Hnatyszyn JH, Lee KP. Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL. J Immunol 2003, 171(4):1780-1789.
45. Kharfan-Dabaja M, Ayala E, Lindner I, Cejas PJ, Bahlis NJ, Kolonias D, Carlson LM, Lee KP. Differentiation of acute and chronic myeloid leukemic blasts into the dendritic cell lineage: analysis of various differentiation-inducing signals. Cancer Immunol Immunothe 2005, 54(1):25-36.
46. Dong R, Cwynarski K, Entwistle A, Marelli-Berg F, Dazzi F, Simpson E, Goldman JM, Melo JV, Lechler RI, Bellantuono I, Ridley A, Lombardi G. Dendritic cells from patients with CML have altered actin organization, reduced antigen processing, and impaired migration. Blood 2003, 101(9):3560-356. 10.1182/blood-2002-06-1841, 12506035.
47. Tong XM, Yao HP, Qian WB, Zhu LF, Fu ZH, Huang ZL, Jin J. The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells. Int J Lab Hematol 2008, 30(5):372-381. 10.1111/j.1751-553X.2007.00986.x, 18205840.
48. Litzow MR, Dietz AB, Bulur PA, Butler GW, Gastineau DA, Hoering A, Fink SR, Letendre L, Padley DJ, Paternoster SF, Tefferi A, Vuk-Pavlović S. Testing the safety of clinical-grade mature autologous myeloid DC in a phase I clinical immunotherapy trial of CML. Cytotherapy 2006, 8(3):290-298. 10.1080/14653240600735743, 16793737.
49. Westermann J, Kopp J, van Lessen A, Hecker AC, Baskaynak G, le Coutre P, Döhner K, Döhner H, Dörken B, Pezzutto A. Vaccination with autologous non-irradiated dendritic cells in patients with bcr/abl + chronic myeloid leukaemia. Br J Haematol 2007, 137(4):297-306. 10.1111/j.1365-2141.2007.06547.x, 17408402.
50. Mumprecht S, Claus C, Schürch C, Pavelic V, Matter MS, Ochsenbein AF. Defective homing and impaired induction of cytotoxic T cells by BCR/ABL-expressing dendritic cells. Blood 2009, 113(19):4681-4689. 10.1182/blood-2008-05-156471, 19252140.
51. Sun JY, Krouse RS, Forman SJ, Senitzer D, Sniecinski I, Chatterjee S, Wong KK. Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 2002, 62(11):3175-3183.
52. Takahashi T, Tanaka Y, Nieda M, Azuma T, Chiba S, Juji T, Shibata Y, Hirai H. Dendritic cell vaccination for patients with chronic myelogenous leukemia. Leuk Res 2003, 27(9):795-80. 10.1016/S0145-2126(03)00011-0, 12804637.
53. Smith BD, Kasamon YL, Kowalski J, Gocke C, Murphy K, Miller CB, Garrett-Mayer E, Tsai HL, Qin L, Chia C, Biedrzycki B, Harding TC, Tu GH, Jones R, Hege K, Levitsky HI. K562/GM-CSF immunotherapy reduces tumor burden in chronic myeloid leukemia patients with residual disease on imatinib mesylate. Clin Cancer Res 2010, 16(1):338-347. 10.1158/1078-0432.CCR-09-2046, 2804932, 20048335.
54. Tao K, Li YJ, Wang D, Qi JY, Deng YP, Wang HX, Hu J, Feng WL. Enhancement of specific cellular immune response induced by glycosyl-phosphatidylinositol-anchored BCR/ABL and mIL-12. Cancer Biol Ther 2011, 12(10):881-887. 10.4161/cbt.12.10.17674, 3280903, 22024730.
55. Grigg A, Szer J. Successful donor leukocyte infusion for chronic myeloid leukemia relapsing in accelerated phase after T cell-replete unrelated marrow transplantation. Bone Marrow Transplant 1996, 18(3):647-648.
56. Huang XJ. Hematopoietic stem cell transplantation in China: current status and prospects. Am J Blood Res 2011, 1(1):90-99. 3301412, 22432069.
57. Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, Han W, Wang Y, Qin YZ, Huang XJ. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012, 119(14):3256-3262. 10.1182/blood-2011-09-380386, 22337715.
58. Rapoport AP, Levine BL, Badros A, Meisenberg B, Ruehle K, Nandi A, Rollins S, Natt S, Ratterree B, Westphal S, Mann D, June CH. Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant 2004, 33(1):53-60. 10.1038/sj.bmt.1704317, 14578928.
59. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004, 103(3):767-776.
60. Kondo Y, Shiobara S, Nakao S. Identification of T-cell clones showing expansion associated with graft-vs-leukemia effect on chronic myelogenous leukemia in vivo and in vitro. Exp Hematol 2001, 29(4):471-476. 10.1016/S0301-472X(01)00615-4, 11301187.
61. Lu YF, Gavrilescu LC, Betancur M, Lazarides K, Klingemann H, Van Etten RA. Distinct graft-versus-leukemic stem cell effects of early or delayed donor leukocyte infusions in a mouse chronic myeloid leukemia model. Blood 2012, 119(1):273-284. 10.1182/blood-2011-01-331009, 3251232, 22072555.
62. Li N, Matte-Martone C, Zheng H, Cui W, Venkatesan S, Tan HS, McNiff J, Demetris AJ, Roopenian D, Kaech S, Shlomchik WD. Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood 2011, 118(22):5965-5976. 10.1182/blood-2011-07-367011, 3228506, 21917752.
63. Quintarelli C, Dotti G, De Angelis B, Hoyos V, Mims M, Luciano L, Heslop HE, Rooney CM, Pane F, Savoldo B. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia. Blood 2008, 112(5):1876-1885. 10.1182/blood-2008-04-150045, 3401035, 18591381.
64. Rezvani K, Yong AS, Tawab A, Jafarpour B, Eniafe R, Mielke S, Savani BN, Keyvanfar K, Li Y, Kurlander R, Barrett AJ. Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. Blood 2009, 113(10):2245-2255. 10.1182/blood-2008-03-144071, 2652370, 18988867.
65. Crough T, Nieda M, Morton J, Bashford J, Durrant S, Nicol AJ. Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia. J Immunother 2002, 25(6):469-475. 10.1097/00002371-200211000-00003, 12439344.
66. Sun JY, Senitzer D, Forman SJ, Chatterjee S, Wong KK. Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes. Cancer Immunol Immunother 2003, 52(12):761-770. 10.1007/s00262-003-0415-6, 14564482.
67. Borchers S, Provasi E, Silvani A, Radrizzani M, Benati C, Dammann E, Krons A, Kontsendorn J, Schmidtke J, Kuehnau W, von Neuhoff N, Stadler M, Ciceri F, Bonini C, Ganser A, Hertenstein B, Weissinger EM. Genetically modified donor leukocyte transfusion and graft-versus-leukemia effect after allogeneic stem cell transplantation. Hum Gene Ther 2011, 22(7):829-841. 10.1089/hum.2010.162, 3135250, 21091264.
68. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, Guggino G, Meraviglia S, Caccamo N, Messina A, Salerno A, Di Raimondo F, Vigneri P, Stassi G, Fourniè JJ, Dieli F. V gamma 9 V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010, 184(6):3260-3268. 10.4049/jimmunol.0903454, 20154204.
69. Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, Morris E. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis 2008, 40(1):113-116. 10.1016/j.bcmd.2007.06.018, 17855129.
70. Yin Q, Zha X, Yang L, Chen S, Zhou Y, Wu X, Li Y. Generation of diffuse large B cell lymphoma-associated antigen-specific Vα6/Vβ13+T cells by TCR gene transfer. J Hematol Oncol 2011, 4:2. 10.1186/1756-8722-4-2, 3024308, 21223579.
71. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314(5796):126-129. 10.1126/science.1129003, 2267026, 16946036.
72. Wang D, Zhang L, Li Y, Wang H, Xiao Q, Cao W, Feng W. Construction and expression of humanized chimeric T cell receptor specific for chronic myeloid leukemia cells. Biotechnol Lett 2012, 34(7):1193-1201. 10.1007/s10529-012-0896-5, 22447097.